BioSpace News Archive

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol ™ , an oral therapy for the treatment of nonalcoholi

- Synlogic ends 2Q2020 with $109.1 million in cash, cash equivalents and investments supporting projected runway into 2022 - - Company continues to advance multiple clinical stage Synthetic Biotic medicines - - Management to host conference call and webcast at 8:00 am ET today -

Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 Preclinical Data Presented at 2020 AACR Virtual Annual Meeting II in June Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors STRO-001 Dose Escalation Ongoing in Phase 1 Clinical Trial for Multiple Myeloma and Lymphoma Sutro’s Partner Merck KGaA, Unveiled Preclinical Data from the Collaboration’s potential First-in-Class Bispecific Antibody-Drug

Sierra Oncology, Inc.today reported its financial and operational results for the second quarter ended June 30, 2020.

Sierra Oncology, Inc. announced the appointments of Mr. Kevin Norrett as Chief Business Officer and Mr. William D. Turner as Chief Regulatory and Technical Operations Officer.

CTP-543 Phase 3 Trial Initiation in Alopecia Areata Expected to Begin Fourth Quarter 2020 CTP-692 Phase 2 Trial Enrollment in Schizophrenia Expected to be Complete by Year-End 2020 Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2020. “We continue to be committed to advancing both of o

Role will build on existing Humanigen Asia-Pacific activities and focus on regional clinical development, commercialization, business and corporate development

PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon, has been named to PharmaVOICE magazine’s annual list of the most inspiring people in the life sciences industry

Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005031/en/ Crown Bioscience Chief Operations Officer Joh

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Uzair Qadeer as the company’s first Chief Diversity Officer.